SPOTLIGHT -
Dr. Berg on Key Ongoing Trials in Metastatic Urothelial Carcinoma
Stephanie A. Berg, DO, discusses key ongoing trials in metastatic urothelial carcinoma.
Read More
Dr. Berg the Promise of Key Updates in Urothelial Cancer
Stephanie A. Berg, DO, discusses the promise of key updates in urothelial cancer, as well as highlights how these updates continue to affect treatment decisions for patients.
Dr. Berg on the Role of the PEACE-1 and ARASENS Trials in Expanding mHSPC Treatment
Stephanie Berg, DO, discusses two key clinical trials that have advanced the standard of care in metastatic hormone-sensitive prostate cancer.
Cabozantinib Plus Nivolumab/Ipilimumab Generates PFS and DCR in Metastatic Soft Tissue Sarcoma
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal Melanoma
Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer
Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC
